Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

INTRODUCTION: Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tof...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Rheumatol Ther
Autors principals: Cohen, Stanley, Curtis, Jeffrey R., DeMasi, Ryan, Chen, Yan, Fan, Haiyun, Soonasra, Arif, Fleischmann, Roy
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2018
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935628/
https://ncbi.nlm.nih.gov/pubmed/29470834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-018-0097-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars